Physician profile
Edwin Roman Brown
NPI 1770506289
$2,306.17
in general payments reported to CMS, 2019-2025
23 companies · $938 in 2025
The $938 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.48 · 2023: $356 · 2024: $986 · 2025: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,279.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $511.77 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $337.66 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $290.94 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $143.49 | 2024-2025 | |
| Pfizer INC. | $111.18 | 2023-2025 | |
| Abbott Laboratories | $109.49 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Abbvie INC. | $95.68 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.17 | 2023-2025 | Xifaxan, Trulance |
| Amgen INC. | $83.74 | 2023-2025 | Otezla, Repatha, Evenity |
| Xeris Pharmaceuticals, INC. | $72.12 | 2023-2024 | Gvoke Hypopen, Recorlev |
| Exact Sciences Corporation | $67.18 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.68 | 2024-2025 | Jardiance |
| Corcept Therapeutics | $50.44 | 2024-2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $44.45 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $43.53 | 2024-2025 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $37.99 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Insulet Corporation | $36.36 | 2024 | Omnipod |
| Lundbeck LLC | $31.05 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $22.86 | 2023 | |
| Daiichi Sankyo INC. | $20.71 | 2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $18.76 | 2023 | |
| Azurity Pharmaceuticals, INC. | $16.46 | 2025 | Alvesco |
| Janssen Pharmaceuticals, INC | $15.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.